The National Cancer Institute (NCI) Molecular Targets Laboratory is seeking parties interested in collaborative research to co-develop antiviral tropolone derivatives developed by systematic medicinal chemistry on the lead series.
NCI seeks partners to commercialize Griffithsin and Griffithsin tandemers as therapeutics for HIV infections that are resistant to native GRFT, specifically, additional studies on stability, toxicity, immunogenicity, and large-scale production.
The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to co-develop antibody-based therapeutic against MERS-CoV, including animal studies, cGMP manufacturing, and clinical trials.